Stock listing
LS Exchange:A3DSHM Lavipharm SA Aktie
German listing (LS Exchange) of Lavipharm SA · home listing ATHEX:LAVI
Follow Lavipharm SA into a list and get an email when it puts out news.
Home listing price · ATHEX:LAVI
€1.45 EUR -0.03 (-1.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, ATHEX:LAVI
- Day range
- €1.41 – €1.48 EURNov 20, 2026
- Volume
- 57,717 sharesNov 20, 2026
- Market cap
- €246.9M EURAt the close on Nov 20, 2026 · price × 170.8M shares outstanding
- 52-week range
- €0.807 – €1.74 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €127,957 EURMedian day 38,050 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ATHEX:LAVI · Home | €1.446 EUR | -0.026 (-1.8%) | 57,717 | €1.48 | €1.48 | €1.414 | €1.472 | Close on Nov 20, 2026 |
| Frankfurt:BXA0 | €1.368 EUR | -0.038 (-2.7%) | — | €1.378 | €1.398 | €1.368 | €1.406 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ATHEX:LAVI · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.446 | -0.026 | -1.8% | €1.48 | €1.48 | €1.414 | 57,717 | |
| €1.472 | -0.01 | -0.7% | €1.478 | €1.486 | €1.46 | 10,001 | |
| €1.482 | -0.004 | -0.3% | €1.472 | €1.496 | €1.47 | 12,055 | |
| €1.486 | +0.01 | +0.7% | €1.48 | €1.52 | €1.48 | 18,246 | |
| €1.476 | -0.002 | -0.1% | €1.464 | €1.51 | €1.452 | 24,567 | |
| €1.478 | -0.002 | -0.1% | €1.48 | €1.49 | €1.474 | 12,900 | |
| €1.48 | -0.01 | -0.7% | €1.49 | €1.49 | €1.47 | 17,801 | |
| €1.49 | +0.002 | +0.1% | €1.49 | €1.492 | €1.47 | 27,586 | |
| €1.488 | +0.038 | +2.6% | €1.47 | €1.50 | €1.448 | 38,383 | |
| €1.45 | -0.05 | -3.3% | €1.496 | €1.498 | €1.444 | 70,019 | |
| €1.50 | -0.026 | -1.7% | €1.53 | €1.53 | €1.498 | 55,023 | |
| €1.526 | +0.046 | +3.1% | €1.50 | €1.534 | €1.49 | 136,016 | |
| €1.48 | -0.02 | -1.3% | €1.472 | €1.498 | €1.472 | 25,253 | |
| €1.50 | -0.036 | -2.3% | €1.534 | €1.534 | €1.49 | 65,872 | |
| €1.536 | +0.006 | +0.4% | €1.538 | €1.538 | €1.50 | 29,482 | |
| €1.53 | +0.004 | +0.3% | €1.526 | €1.54 | €1.514 | 35,375 | |
| €1.526 | +0.008 | +0.5% | €1.536 | €1.536 | €1.49 | 41,045 | |
| €1.518 | +0.066 | +4.5% | €1.48 | €1.55 | €1.47 | 45,193 | |
| €1.452 | -0.018 | -1.2% | €1.48 | €1.508 | €1.432 | 47,951 | |
| €1.47 | -0.028 | -1.9% | €1.48 | €1.484 | €1.47 | 40,491 | |
| €1.498 | -0.008 | -0.5% | €1.484 | €1.518 | €1.484 | 103,540 | |
| €1.506 | -0.004 | -0.3% | €1.486 | €1.506 | €1.47 | 38,050 | |
| €1.51 | +0.002 | +0.1% | €1.51 | €1.53 | €1.48 | 9,207 | |
| €1.508 | -0.002 | -0.1% | €1.486 | €1.518 | €1.486 | 6,052 | |
| €1.51 | +0.002 | +0.1% | €1.48 | €1.51 | €1.48 | 31,861 | |
| €1.508 | +0.002 | +0.1% | €1.528 | €1.53 | €1.482 | 42,915 | |
| €1.506 | -0.014 | -0.9% | €1.53 | €1.56 | €1.498 | 46,701 | |
| €1.52 | +0.01 | +0.7% | €1.56 | €1.56 | €1.492 | 39,045 | |
| €1.51 | 0.00 | 0.0% | €1.518 | €1.54 | €1.494 | 34,442 | |
| €1.51 | -0.02 | -1.3% | €1.53 | €1.54 | €1.462 | 87,323 | |
| €1.53 | -0.03 | -1.9% | €1.55 | €1.55 | €1.498 | 223,278 | |
| €1.56 | 0.00 | 0.0% | €1.56 | €1.586 | €1.544 | 19,947 | |
| €1.56 | -0.008 | -0.5% | €1.568 | €1.586 | €1.544 | 33,384 | |
| €1.568 | +0.018 | +1.2% | €1.568 | €1.582 | €1.538 | 42,029 | |
| €1.55 | -0.024 | -1.5% | €1.574 | €1.576 | €1.55 | 14,315 | |
| €1.574 | +0.004 | +0.3% | €1.58 | €1.58 | €1.56 | 12,795 | |
| €1.57 | +0.002 | +0.1% | €1.58 | €1.58 | €1.554 | 16,420 | |
| €1.568 | -0.002 | -0.1% | €1.586 | €1.59 | €1.54 | 34,549 | |
| €1.57 | -0.008 | -0.5% | €1.58 | €1.58 | €1.556 | 14,996 | |
| €1.578 | 0.00 | 0.0% | €1.588 | €1.588 | €1.554 | 37,839 | |
| €1.578 | +0.014 | +0.9% | €1.59 | €1.59 | €1.56 | 225,877 | |
| €1.564 | -0.036 | -2.3% | €1.60 | €1.60 | €1.564 | 577,861 | |
| €1.60 | -0.006 | -0.4% | €1.612 | €1.614 | €1.58 | 101,215 | |
| €1.606 | -0.004 | -0.2% | €1.60 | €1.62 | €1.582 | 291,398 | |
| €1.61 | +0.02 | +1.3% | €1.566 | €1.61 | €1.566 | 97,120 | |
| €1.59 | +0.01 | +0.6% | €1.586 | €1.61 | €1.56 | 116,996 | |
| €1.58 | +0.032 | +2.1% | €1.534 | €1.58 | €1.534 | 181,580 | |
| €1.548 | -0.02 | -1.3% | €1.58 | €1.58 | €1.54 | 167,207 | |
| €1.568 | -0.022 | -1.4% | €1.60 | €1.60 | €1.552 | 24,032 | |
| €1.59 | -0.008 | -0.5% | €1.598 | €1.60 | €1.564 | 29,278 | |
| €1.598 | -0.022 | -1.4% | €1.62 | €1.62 | €1.58 | 35,534 | |
| €1.62 | +0.018 | +1.1% | €1.608 | €1.62 | €1.584 | 69,340 | |
| €1.602 | -0.008 | -0.5% | €1.608 | €1.608 | €1.582 | 28,289 | |
| €1.61 | -0.01 | -0.6% | €1.602 | €1.618 | €1.58 | 56,668 | |
| €1.62 | -0.002 | -0.1% | €1.64 | €1.64 | €1.598 | 24,809 | |
| €1.622 | -0.018 | -1.1% | €1.65 | €1.65 | €1.59 | 85,748 | |
| €1.64 | -0.008 | -0.5% | €1.64 | €1.666 | €1.62 | 36,306 | |
| €1.648 | +0.006 | +0.4% | €1.678 | €1.678 | €1.632 | 13,277 | |
| €1.642 | +0.002 | +0.1% | €1.64 | €1.672 | €1.632 | 32,871 | |
| €1.64 | -0.008 | -0.5% | €1.618 | €1.69 | €1.618 | 57,611 | |
| €1.648 | +0.002 | +0.1% | €1.652 | €1.68 | €1.644 | 333,147 | |
| €1.646 | +0.086 | +5.5% | €1.568 | €1.65 | €1.568 | 452,594 | |
| €1.56 | -0.004 | -0.3% | €1.55 | €1.584 | €1.544 | 511,677 | |
| €1.564 | +0.01 | +0.6% | €1.54 | €1.582 | €1.54 | 26,845 | |
| €1.554 | -0.012 | -0.8% | €1.57 | €1.58 | €1.55 | 23,820 |
Splits
8 splits since 1997 · ATHEX:LAVI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1.0743-for-1 | Split | |
| 1-for-3 | Consolidation | |
| 89-for-83 | Split | |
| 73-for-55 | Split | |
| 2-for-1 | Split | |
| 11-for-10 | Split | |
| 95-for-89 | Split | |
| 6-for-5 | Split |
- Ticker
- LS Exchange:A3DSHM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- LS Exchange
- Currency
- EUR
What changed lately
Latest news release · Sep 3, 2026
Announcement Appointment of Chief Manufacturing & Operations Officer
Latest deck · Apr 27, 2026
Investor Presentation (April 2026)
Investor deck · 35 slides
Latest news
Announcement Appointment of Chief Manufacturing & Operations Officer
Sep 3, 2026
Closed €1.62 (-0.1%) on Sep 3, 2026
Announcement Appointment of Chief Quality Officer
Jun 11, 2026
Closed €1.54 (-0.3%) on Jun 11, 2026
Lavipharm SA on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 2 in the last 12 months · 13 in all · newest Sep 3, 2026 · oldest 2023
- Decks
- 3 decks · latest Apr 27, 2026
Where Lavipharm SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ATHEX:LAVI · Home listing | ATHEX | Greece | EUR |
| Lang & Schwarz:A3DSHM | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3DSHM · This page | LS Exchange | Germany | EUR |
| Frankfurt:BXA0 | Frankfurt | Germany | EUR |
| LSE:0KDJ | LSE | United Kingdom | EUR |
Valuation
P/E 41.2× against a median of 52.5×: 2nd lowest of 5 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €281.6M EUR
- P/E
- 41.2×
- EV/sales
- 4.5×
- EV/EBITDA
- 22.8×
- Price/book
- 4.4×
- Gross margin
- 46.0%
- Operating margin
- 11.4%
- Net margin
- 9.6%
- Debt to equity
- 0.7×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lavipharm SA · ATHEX:LAVI | US$271.0M | US$309.1M | 41.2× | 4.5× | 22.8× | 4.4× | 9.6% | 0.7× | n/a |
| Chengdu Huasun Technology Group Inc., Ltd. Class A · SZSE:000790 | US$285.5M | US$277.5M | n/a | 4.4× | n/a | 2.7× | −57.2% | 0.1× | n/a |
| Tiansheng Pharmaceutical Group Co. Ltd. Class A · SZSE:002872 | US$279.7M | US$239.5M | n/a | 3.1× | n/a | 1.0× | −10.6% | 0.0× | n/a |
| Bukwang Pharmaceutical Co., Ltd. · KRX:003000 | US$278.6M | US$153.0M | 42.7× | 1.0× | n/a | 1.1× | 4.1% | 0.0× | n/a |
| Ildong Pharmaceutical Co., Ltd. · KRX:249420 | US$278.0M | US$233.1M | 8.6× | 0.5× | 6.3× | 1.4× | 7.5% | 0.0× | n/a |
| Deva Holding A.S. · BIST:DEVA | US$276.9M | US$245.0M | n/a | 0.6× | 4.4× | 0.4× | −3.9% | 0.1× | n/a |
| Honz Pharmaceutical Co., Ltd. Class A · SZSE:300086 | US$276.0M | US$298.2M | n/a | 5.9× | n/a | 2.2× | −62.4% | 0.2× | n/a |
| Shandong Sito Bio-technology Co., Ltd. Class A · SZSE:300583 | US$272.2M | US$254.6M | 62.3× | 1.5× | n/a | 1.0× | 2.6% | 0.1× | n/a |
| Zhejiang East Asia Pharmaceutical Co., Ltd. Class A · SSE:605177 | US$264.1M | US$340.3M | n/a | 2.4× | n/a | 1.1× | −21.8% | 0.5× | n/a |
| Jilin Jian Yisheng Pharmaceutical Co., Ltd. Class A · SZSE:002566 | US$260.3M | US$189.9M | 66.4× | 2.1× | n/a | 0.8× | 4.4% | 0.1× | n/a |
| Emergent BioSolutions Inc. · NYSE:EBS | US$259.6M | US$598.2M | n/a | 0.9× | n/a | 0.8× | −40.2% | 1.6× | 1.17 |
| Median of the others | US$276.4M | US$249.8M | 52.5× | 1.8× | 5.3× | 1.1× | −7.2% | 0.1× | 1.17 |
Team and board
Officers
| Officer | Role |
|---|---|
| Telemaque Jean Lavidas | Chief Executive Officer |
| Vassilis Baloumis | Chief Financial Officer |
| Vivienne Thomas | Lead Corporate Communications |
| Loukia Lavida | Board Vice President |
| Anastasios Spyropoulos | Chief Manufacturing & Operations Officer |
| Artemis Papadaki | Chief Commercial Officer Hellas |
| Efi Douni | Marketing Director Rx |
| Eleana Nikolopoulou | Director of Legal & Compliance |
| Emmanouil Petrou | Head of Medical Affairs |
| Ilias Konstantopoulos | Director of Marketing & Sales CHC |
| Ioannis Sarigiannidis | Chief Commercial Officer International |
| Katerina Karapa | Chief Quality Officer |
| Ligia Panaitescu | Director of Research & Development |
| Mariza Antonaki | Chief People & Technology Officer |
| Nikos Ladas | Chief Scientific Officer |
| Panagiotis Giannouleas | Deputy Chief Executive Officer |
| Roxani Skartsiouni | Director of Supply Chain & Planning |
Board
| Director | Role |
|---|---|
| Sofia Kounenaki Efraimoglou | Chairperson of the Board |
| Christos Diamandopoulos | Non-Executive Board Member |
| James Christopoulos | Independent, Non-Executive Board Member |
| Konstantinos Rengis | Non-Executive Board Member |
| Loukia Lavida | Board Vice President |
| Panagiotis Giannouleas | Deputy Chief Executive Officer |
| Telemaque Jean Lavidas | Chief Executive Officer |
| Vicky D. Kefalas | Independent, Non-Executive Board Member |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2026) | Investor deck | 35 slides | Apr 27, 2026 |
| FY2023 Earnings Presentation | Earnings | 36 slides | Apr 24, 2024 |
| Investor Presentation (2014) | Investor deck | 25 slides | 2014 |
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.6M | 52.9M | 50.9M | 39.1M | 39.7M | 37.6M | 33.6M | 31.8M | 31.6M | 32.0M |
| Cost of revenue | 33.8M | 29.2M | 27.7M | 22.7M | 25.0M | 22.5M | 18.6M | 17.0M | 17.3M | 17.5M |
| Gross profit | 28.8M | 23.7M | 23.2M | 16.4M | 14.7M | 15.1M | 14.9M | 14.7M | 14.2M | 14.6M |
| Research and development | 344.0K | 285.0K | 195.0K | 365.0K | 812.0K | 753.0K | 290.0K | 410.0K | 299.0K | 249.0K |
| Selling, general and administrative | 2.85M | 2.46M | 2.62M | 2.33M | 2.49M | 2.67M | 13.8M | 15.1M | 15.0M | 17.5M |
| Operating income | 7.16M | 4.26M | 4.18M | 2.69M | -398.0K | 1.96M | 876.0K | -370.0K | 1.19M | -2.63M |
| Depreciation and amortization | 5.21M | 4.58M | 4.21M | 1.71M | 1.65M | 1.57M | 1.42M | 1.18M | 2.21M | 3.45M |
| EBITDA | 12.4M | 8.84M | 8.39M | 4.39M | 1.25M | 3.53M | 2.30M | 814.0K | 3.40M | 820.0K |
| Interest expense | 1.84M | 2.09M | 2.27M | 1.64M | 1.83M | 1.92M | 1.93M | 1.93M | 1.99M | 4.60M |
| Income before tax | 7.50M | 3.60M | 3.25M | 2.26M | 2.75M | 3.31M | 2.12M | 2.86M | 12.9M | 11.7M |
| Income tax | 2.45M | -5.06M | 1.25M | 1.31M | 1.02M | 1.21M | -3.21M | 1.61M | -37.0K | 2.81M |
| Net income | 5.99M | 8.98M | 1.87M | 834.0K | 1.72M | 2.09M | 5.33M | 1.25M | 12.9M | 3.66M |
| Earnings per share, basic | 0.04 | 0.05 | 0.01 | 0.04 | 0.09 | 0.11 | 0.29 | 0.07 | 0.71 | 0.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 6.11M | 5.59M | 8.44M | 18.2M | 1.64M | 1.93M | 1.73M | 1.84M | 2.35M | 1.68M |
| Short-term investments | 3.00K | 1.00K | 12.0K | 44.0K | ||||||
| Receivables | 22.6M | 16.1M | 21.7M | 15.4M | 14.5M | 9.88M | 12.5M | 11.6M | 11.3M | 13.1M |
| Inventory | 23.2M | 20.8M | 14.8M | 10.9M | 9.59M | 8.42M | 6.49M | 4.90M | 5.76M | 6.29M |
| Current assets | 53.2M | 45.0M | 45.7M | 45.6M | 26.0M | 23.3M | 20.7M | 18.6M | 19.9M | 21.3M |
| Property, plant and equipment | 17.1M | 17.6M | 17.0M | 17.2M | 15.3M | 15.3M | 18.6M | |||
| Total assets | 130.7M | 125.7M | 114.8M | 114.3M | 53.0M | 50.6M | 49.9M | 41.9M | 44.9M | 48.7M |
| Accounts payable | 9.75M | 8.32M | 9.96M | 7.77M | 6.36M | 2.74M | 6.03M | 4.43M | 3.75M | 3.94M |
| Current liabilities | 44.0M | 39.1M | 35.8M | 45.7M | 23.2M | 18.8M | 17.4M | 14.7M | 19.5M | 41.9M |
| Long-term debt | 10.2M | 12.2M | 12.7M | 3.96M | 4.00M | 24.0M | 25.7M | 26.7M | 39.8M | 56.8M |
| Total debt | 28.4M | 33.8M | 32.4M | 37.1M | 37.3M | 36.3M | 40.7M | 40.5M | 41.5M | 79.1M |
| Total liabilities | 74.3M | 72.7M | 72.1M | 74.0M | 62.9M | 62.9M | 64.3M | 61.4M | 64.8M | 105.6M |
| Shareholders' equity | 56.4M | 53.0M | 42.7M | 40.3M | -9.98M | -12.3M | -14.4M | -19.5M | -19.9M | -31.8M |
| Shares outstanding | 169.2M | 168.5M | 168.2M | 21.5M | 18.3M | 18.3M | 18.3M | 18.3M | 18.3M | 18.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 6.72M | 4.80M | 539.0K | 3.37M | 3.84M | 2.85M | 2.90M | 1.43M | 1.54M | 622.0K |
| Capital spending | -4.62M | -9.64M | -4.12M | -35.6M | -1.92M | -1.48M | -2.42M | -1.03M | -350.0K | -97.0K |
| Free cash flow | 2.10M | -4.85M | -3.58M | -32.2M | 1.92M | 1.38M | 483.0K | 398.0K | 1.19M | 525.0K |
| Cash from investing | -993.0K | -9.66M | -3.71M | -35.6M | -1.91M | -1.48M | -2.41M | -1.03M | 250.0K | 418.0K |
| Cash from financing | -5.35M | 2.16M | -6.63M | 48.8M | -2.23M | -1.18M | -595.0K | -904.0K | -1.11M | 97.0K |
| Dividends paid | -3.38M | |||||||||
| Share buybacks | -200.0K | 0 | -2.50M | 49.3M | ||||||
| Change in cash | 517.0K | -2.85M | -9.81M | 16.6M | -294.0K | 200.0K | -110.0K | -506.0K | 673.0K | 1.14M |
Cap table
Built by 6ix from Lavipharm SA’s releases
- Common shares
- 170,778,483
- Fully diluted
- 170,778,483
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 170,778,483 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 170,778,483 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anastasios Spyropoulos | Chief Manufacturing & Operations Officer · Since at least Sep 3, 2026 |
| Artemis Papadaki | Chief Commercial Officer Hellas · Since at least Nov 5, 2026 |
| Christos Diamandopoulos | Non-Executive Board Member · Since at least Nov 5, 2026 |
| Efi Douni | Marketing Director Rx · Since at least Nov 5, 2026 |
| Eleana Nikolopoulou | Director of Legal & Compliance · Since at least Nov 4, 2026 |
| Emmanouil Petrou | Head of Medical Affairs · Since at least Nov 5, 2026 |
| Ilias Konstantopoulos | Director of Marketing & Sales CHC · Since at least Nov 5, 2026 |
| Ioannis Sarigiannidis | Chief Commercial Officer International · Since at least Nov 5, 2026 |
| James Christopoulos | Independent, Non-Executive Board Member · Since at least Nov 5, 2026 |
| Katerina Karapa | Chief Quality Officer · Since at least Jun 11, 2026 |
All 22 people
| Person | Seat |
|---|---|
| Konstantinos Rengis | Non-Executive Board Member · Since at least Nov 5, 2026 |
| Ligia Panaitescu | Director of Research & Development · Since at least Nov 5, 2026 |
| Loukia Lavida | Board Vice President · Since at least Nov 5, 2026 |
| Mariza Antonaki | Chief People & Technology Officer · Since at least Nov 5, 2026 |
| Nikos Ladas | Chief Scientific Officer · Since at least Nov 5, 2026 |
| Panagiotis Giannouleas | Deputy Chief Executive Officer · Since at least Nov 5, 2026 |
| Roxani Skartsiouni | Director of Supply Chain & Planning · Since at least Nov 5, 2026 |
| Sofia Kounenaki Efraimoglou | Chairperson of the Board · Since at least Nov 5, 2026 |
| Telemaque Jean Lavidas | Chief Executive Officer · Since at least Jan 23, 2025 |
| Vassilis Baloumis | Chief Financial Officer · Since at least Sep 18, 2025 |
| Vicky D. Kefalas | Independent, Non-Executive Board Member · Since at least Nov 4, 2026 |
| Vivienne Thomas | Lead Corporate Communications · Since at least Sep 3, 2026 |
Log in to ask 6ix AI your own questions about Lavipharm SA.